Track Tarsus Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Tarsus Pharmaceuticals, Inc. TARS · Stock Open Tarsus Pharmaceuticals, Inc. in new tab

80.28 USD
EPS
-15.86
P/B
38.05
ROE
-319.84
Beta
0.33
Target Price
103.44 USD
Loading chart...
Key Metrics
Earnings dateFeb. 22, 2027
EPS-15.86
Book Value2.11
Price to Book38.05
Debt/Equity85.97
% Insiders3.641%
Growth
Revenue Growth0.64%
Estimates
Forward P/E373.40
Forward EPS0.22
Target Mean Price103.44

DCF valuation

Model fair value for Tarsus Pharmaceuticals, Inc. (TARS)
Result
Sign in to run the valuation for TARS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
9 analysts · consensus Strong buy · mean target 103.44 USD (low 88.00, high 116.00) · as of 14 Nov 2026
Low 88.00
Mean 103.44
High 116.00
Price 80.28
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Tarsus Pharmaceuticals, Inc. Logo Tarsus Pharmaceuticals, Inc. Analysis (TARS)

United States Health Care Official Website Stock

Is Tarsus Pharmaceuticals, Inc. a good investment? Tarsus Pharmaceuticals, Inc. (TARS) is currently trading at 80.28 USD. Market analysts have a consensus price target of 103.44 USD. This suggests a potential upside from current levels.

Earnings Schedule: Tarsus Pharmaceuticals, Inc. is expected to release its next earnings report on Feb. 22, 2027. The market consensus estimate for Forward EPS is 0.22.

Investor FAQ

Does Tarsus Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Tarsus Pharmaceuticals, Inc.?

Tarsus Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 22, 2027. The company currently has a trailing EPS of -15.86.

Company Profile

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Exchange Ticker
NMS (United States) TARS
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion